Endocrinology and Metabolism

Original Articles

APOA5 Polymorphism Is Associated with Metabolic Syndrome in Korean Postmenopausal Women.: Doh Hee Kim, Seung Hee Lee, Kyung Hoon Han, Chae Bong Kim, Kwan Young Song, Sook Cho, Kye Heui Lee; Endocrinol Metab. 2012;27(4):276-281. Published online December 20, 2012; DOI: https://doi.org/10.3803/EnM.2012.27.4.276

5,826 View
24 Download
2 Crossref

BACKGROUND
Menopause is an independent risk factor in metabolic syndrome which induced an alteration of the lipid metabolism by hormonal changes. Apolipoprotein A5 gene (APOA5) was related to the regulation of triglyceride and high density lipoprotein cholesterol (HDL-C) level with biosynthesis and decomposition. This study was conducted to investigate the relationship between APOA5 polymorphism and metabolic syndrome in Korean postmenopausal women. METHODS: This study included 307 postmenopausal women with anthropometric and biochemical measurement in 2010-2011. The polymorphism of APOA5 was analyzed by polymerase chain reaction-restriction fragment length polymorphism method with MseI restriction enzyme. RESULTS: The metabolic syndrome prevalence with TT genotype was significantly lower than the frequency in those with TC/CC (27.09%, 38.46%, and 45.71% for TT, TC, and CC, respectively; P < 0.05). Multiple regression analysis of metabolic syndrome risk factors indicated that postmenopausal women with CC genotype had a higher risk with 3 times than that in TT genotype (P < 0.05). APOA5 C carriers showed an increased risk of triglyceride level (odd ratio, 2.93 and 1.85 for CC and TC+CC, respectively; P < 0.05). Interestingly, HDL-C was related to triglyceride directly in comparison to APOA5. CONCLUSION: The results of this study indicate that APOA5 has an influence on serum triglyceride and HDL-C, which contribute to metabolic syndrome in Korean postmenopausal women.

Citations

Citations to this article as recorded by

Effects of a 3-year dietary intervention on age-related changes in triglyceride and apolipoprotein A-V levels in patients with impaired fasting glucose or new-onset type 2 diabetes as a function of the APOA5 -1131 T > C polymorphism
Minjoo Kim, Jey Sook Chae, Miri Kim, Sang-Hyun Lee, Jong Ho Lee
Nutrition Journal.2014;[Epub] CrossRef
APOA5Polymorphism Is Associated with Metabolic Syndrome in Korean Postmenopausal Women
Mi Hae Seo, Won Young Lee
Endocrinology and Metabolism.2012; 27(4): 274. CrossRef

Lipid Profile Changes in Postmenopausal Korean Women Treated with Alendronate (10 mg) for 2 Years: Comparing with Control Group.: Il Woo Joo, Han Jin Oh; J Korean Endocr Soc. 2007;22(1):19-25. Published online February 1, 2007; DOI: https://doi.org/10.3803/jkes.2007.22.1.19

2,989 View
21 Download
1 Crossref

Abstract PDF

BACKGROUND
Bisphosphonate, which has been used for prevention and treatment of osteoporosis with the mechanism of inhibiting bone resorption, also has an association with the cholesterol synthethic process. This suggests that bisphosphonate might have benefit to improve the lipid profile in humans through a process that blocks the mevalonate-squalene pathway. However, few reports have revealed the relationship between the action of bisphosphonate and lipid metabolism in postmenopausal Korean women. We planned this study to determine the effect of alendronate (10 mg) on the serum lipid level in postmenopausal Korean women. Subjects and METHODS: We retrospectively evaluated the postmenopausal Korean women (aged over 50) who visited the Osteoporosis clinic in the Health Care Center in Seoul from March of 2003 to October of 2005. The changes of the serum lipid levels, including total cholesterol, triglyceride, and HDL cholesterol, after 2-years of alendronate 10 mg administration were evaluated and comparing to a control group. RESULTS: After 2-years alendronate (10 mg) administration, the total cholesterol was decreased by 11.8 +/- 3.7 mg/dL, and the HDL cholesterol was increased by 5.2 +/-1.4 mg/dL as compared to the baseline lipid level. Both of these results showed statistical significance. Changes of the triglyceride and fasting blood glucose also showed a decline by 15.4 +/-9.8 mg/dL and 6.0 +/-1.4 mg/dL, respectively, but this was not statistically significant. However, in the control group, the total cholesterol was increased by 9.4 +/-8.8 mg/dL, and the triglyceride was increased by 10.5 +/-7.2 mg/dL as compared to the baseline lipid level. Both of the results showed statistical significance. CONCLUSION: Alendronate might have a beneficial effect on lipid metabolism to decrease cholesterol and increase HDL. Taking into consideration about the postmenopausal increase in the cholesterol level, alendronate is recommended for the prevention of hyperlipidemia in postmenopausal women, in addition to preventing and treating osteoporosi

Citations

Citations to this article as recorded by

The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes
Maryam Karimifard, Ashraf Aminorroaya, Massoud Amini, Ali Kachuie, Awat Feizi, Sima Aminorroaya Yamini, Moluk Hadi Alijanvand
Journal of Research in Medical Sciences.2021; 26(1): 52. CrossRef

Serum Lipoprotein (a) and Lipid Concentrations in Patients with Subelinical Hypothyroidism.: Kyoung Ah Kim, Jae Hoon Chung, Yeun Sun Kim, Kyu Jeung Ahn, Eun Mi Koh, Young Ki Min, Myung Shik Lee, Moon Kyu Lee, Jong Hun Lee, Kwang Won Kim; J Korean Endocr Soc. 1997;12(1):11-17. Published online January 1, 2001

1,678 View
17 Download

Abstract PDF: BACKGROUND
Overt hypothyroidism is well-known cause of secondary hyperlipidemia and atherosclerosis. However, there have been dissenting reports of abnormalities in serum lipid concentrations in patients with subclinical hypothyroidism (SH). Recently, it has been reported that serum Lp (a) concentration, an independent risk factor of atherosclerosis, was increased in patients with SH. Therefore, we analyzed serum Lp (a) and other lipid concentrations to investigate whether they are increased in patients with SH and the correlation between serum Lp (a) and TSH concentrations. METHODS: We undertook this study in 53 patients with SH (TSH > 6 uiU/ml) and 197 age-and sex-matched healthy control subjects, They had no abnormalities in liver function, BUN, creatinine, fasting blood glucose, urinalysis, and past medical histories. Serum T3, T4, and TSH concentrations were measured by RIA using commercial kits. Serum concentrations of Lp (a), total cholesterol, triglyceride (TG), and HDL cholesterol (HDL-C) were measured by rate nephelometry and enzyme assay, respectively. RESULTS: There were no significant differences of serum Lp (a), total cholesterol, LDL cholesterol, TG, and HDL-C concentrations in 53 patients with SH and 197 control subjects (25.6+-3.8mg/dL vs. 25.4+-1.5mg/dL ; 204.0+-4.2mg/dL vs. 204.0+-2.4mg/dL ; 127.0+-3.9mg/dL vs. 125.0+-2.3 mg/dL ; 133.0+-8.5mg/dL vs. 130.0+-6.0mg/dL ; 50.0+-1.5mg/dL vs. 53.0+-0.9mg/dL). There was no correlation between Lp (a) and TSH concentrations in SH (r=0.12, p>0.05). CONCLUSION: Serum Lp (a) concentration as well as total cholesterol, LDL cholesterol, and TG was not increased in patients with SH. There was no correlation between serum Lp (a) and TSH levels in subclinical hypothyroidism.

First
Prev
Page of 1
Next
Last

Search